P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971412.45898.1a |
| _version_ | 1797280875841323008 |
|---|---|
| author | Martin Hutchings Carmelo Carlo-Stella Franck Morschhauser Michael Dickinson Emmanuel Bachy Guillaume Cartron Cyrus Khan Monica Tani Joaquín Martinez-Lopez Nancy L. Bartlett Antonio Salar Joshua Brody Sirpa Leppa Pauline Baumlin Linda Lundberg James Relf Yuying Xie Alessia Bottos Kathryn Humphrey Lorenzo Falchi |
| author_facet | Martin Hutchings Carmelo Carlo-Stella Franck Morschhauser Michael Dickinson Emmanuel Bachy Guillaume Cartron Cyrus Khan Monica Tani Joaquín Martinez-Lopez Nancy L. Bartlett Antonio Salar Joshua Brody Sirpa Leppa Pauline Baumlin Linda Lundberg James Relf Yuying Xie Alessia Bottos Kathryn Humphrey Lorenzo Falchi |
| author_sort | Martin Hutchings |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:47:33Z |
| format | Article |
| id | doaj.art-c4495cc7d2714f60818218c0cb6a1f50 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:47:33Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-c4495cc7d2714f60818218c0cb6a1f502024-03-03T06:25:11ZengWileyHemaSphere2572-92412023-08-017e458981a10.1097/01.HS9.0000971412.45898.1a202308003-01027P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDYMartin Hutchings0Carmelo Carlo-Stella1Franck Morschhauser2Michael Dickinson3Emmanuel Bachy4Guillaume Cartron5Cyrus Khan6Monica Tani7Joaquín Martinez-Lopez8Nancy L. Bartlett9Antonio Salar10Joshua Brody11Sirpa Leppa12Pauline Baumlin13Linda Lundberg14James Relf15Yuying Xie16Alessia Bottos17Kathryn Humphrey18Lorenzo Falchi191 Rigshospitalet, Copenhagen, Denmark2 Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy3 Hôpital Claude Huriez and CHU de Lille, Lille, France4 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia5 Centre Hospitalier Lyon-Sud, Lyon, France6 CHU de Montpellier, Montpellier, France7 Allegheny Health Network, Pittsburgh, PA, United States8 Ospedale Santa Maria delle Croci, Ravenna, Italy9 Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, 28041 Madrid, Spain10 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States11 Department of Hematology, Hospital del Mar, Passeig Maritim, 08003 Barcelona, Spain12 Tisch Cancer Institute, New York, NY, United States13 University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland14 F. Hoffmann-La Roche Ltd, Basel, Switzerland14 F. Hoffmann-La Roche Ltd, Basel, Switzerland15 Roche Products Ltd, Welwyn Garden City, United Kingdom16 F. Hoffmann-La Roche Ltd, Mississauga, Canada14 F. Hoffmann-La Roche Ltd, Basel, Switzerland15 Roche Products Ltd, Welwyn Garden City, United Kingdom17 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000971412.45898.1a |
| spellingShingle | Martin Hutchings Carmelo Carlo-Stella Franck Morschhauser Michael Dickinson Emmanuel Bachy Guillaume Cartron Cyrus Khan Monica Tani Joaquín Martinez-Lopez Nancy L. Bartlett Antonio Salar Joshua Brody Sirpa Leppa Pauline Baumlin Linda Lundberg James Relf Yuying Xie Alessia Bottos Kathryn Humphrey Lorenzo Falchi P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY HemaSphere |
| title | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_full | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_fullStr | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_full_unstemmed | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_short | P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY |
| title_sort | p1129 glofitamab monotherapy in patients with relapsed refractory r r large b cell lymphoma lbcl extended follow up and landmark analyses from a pivotal phase ii study |
| url | http://journals.lww.com/10.1097/01.HS9.0000971412.45898.1a |
| work_keys_str_mv | AT martinhutchings p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT carmelocarlostella p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT franckmorschhauser p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT michaeldickinson p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT emmanuelbachy p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT guillaumecartron p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT cyruskhan p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT monicatani p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT joaquinmartinezlopez p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT nancylbartlett p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT antoniosalar p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT joshuabrody p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT sirpaleppa p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT paulinebaumlin p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT lindalundberg p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT jamesrelf p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT yuyingxie p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT alessiabottos p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT kathrynhumphrey p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy AT lorenzofalchi p1129glofitamabmonotherapyinpatientswithrelapsedrefractoryrrlargebcelllymphomalbclextendedfollowupandlandmarkanalysesfromapivotalphaseiistudy |